Favourable use of non-boosted fosamprenavir in patients treated with warfarin

Abstract

2 Cavalcanti AL, Bagnoli VR, Fonseca AM, et al. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115-9 3 Laan E, van Driel EM, van Lunsen RH. Genital responsiveness in healthy women with and without sexual arousal disorder. J Sex Med 2008;5:1424-35 4 Suschinsky KD, Lalumiere ML, Chivers ML. Sex differences in patterns of genital sexual arousal: measurement artefacts or true phenomena? Arch Sex Behav 2008; (epub ahead of print) 5 Chivers ML, Rieger G, Latty E, Bailey JM. A sex difference in the specificity of sexual arousal. Psychol Sci 2004;15:736 -44 6 Rellini AH, McCall KM, Randall PK, Meston CM. The relationship between women's subjective and physiological sexual arousal. Psychophysiology 2005;42:116-24

Raltegravir can be used safely in HIV-1-infected patients treated with warfarin

“…We reported previously the favourable effects of non-boosted fosamprenavir in patients treated with warfarin. 5 The clinical use of warfarin co-administered with raltegravir has not been described so far, though raltegravir seems to be a safe choice because it does not inhibit or induce CYP isoenzymes. 6 We describe here five HIV-1-infected patients on treatment with warfarin in whom the use of raltegravir was associated with a favourable outcome (Table 1).…”